Gene:
CETP
cholesteryl ester transfer protein, plasma

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1532624 10619678C>A, 14645C>A, 57005479C>A, 658+186C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs1800775 -656C>A, 10609435C>A, 4402C>A, 56995236C>A, CETP:-629C>A
C > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs3764261 10607523C>A, 2490C>A, 56993324C>A
C > A
Not Available
No VIP available CA VA
rs4783961 -998G>A, 10609093G>A, 4060G>A, 56994894G>A
G > A
5' Flanking
No VIP available CA VA
rs5882 10630291G>A, 1264G>A, 25258G>A, 57016092G>A, CETP:I405V, CETP:Ile405Val, CETP:rs5882 A>G
G > A
Missense
Val422Ile
No VIP available No Clinical Annotations available VA
rs5883 10621552C>T, 16519C>T, 57007353C>T, 861C>T, Phe287=
C > T
Synonymous
Phe287Phe
No VIP available CA VA
rs708272 10610487G>A, 118+279G>A, 5454G>A, 56996288G>A, A allele = B2 = not cut by TaqI, CETP:Taq1B, G allele = B1 = cut by TaqI
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs9930761 10621391T>C, 16358T>C, 57007192T>C, 751-51T>C
T > C
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  BPI fold containing family F
Alternate Symbols:  BPIFF
PharmGKB Accession Id: PA108

Details

Cytogenetic Location: chr16 : q21 - q13
GP mRNA Boundary: chr16 : 56995835 - 57017756
GP Gene Boundary: chr16 : 56985835 - 57020756
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. HDL-mediated lipid transport - (Reactome via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
hmg coa reductase inhibitors

Curated Information ?

Publications related to CETP: 26

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events. Clinical pharmacology and therapeutics. 2013. Leusink M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. Journal of lipid research. 2012. Krauss Ronald M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PloS one. 2012. Papp Audrey C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. The pharmacogenomics journal. 2011. de Keyser C E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women. Journal of lipid research. 2010. Hamrefors Viktor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA : the journal of the American Medical Association. 2010. Sanders Amy E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects. Clinical pharmacology and therapeutics. 2009. Wolk R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS computational biology. 2009. Xie Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes. Pharmacogenetics and genomics. 2008. Knouff Christopher W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. European heart journal. 2008. Regieli Jakub J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circulation. Cardiovascular genetics. 2008. Chasman Daniel I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenetics and genomics. 2008. Hindorff Lucia A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol. American journal of human genetics. 2007. Spirin Victor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of lipid research. 2007. Singer Jonathan B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and genomics. 2007. Arnedo Mireia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. Expert opinion on pharmacotherapy. 2007. Anagnostopoulou Katherine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CETP inhibitors to increase HDL cholesterol levels. The New England journal of medicine. 2007. Tall Alan R. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of torcetrapib in patients at high risk for coronary events. The New England journal of medicine. 2007. Barter Philip J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis. 2006. Bercovich Dani, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. European journal of human genetics : EJHG. 2005. Mohrschladt Martina F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An association study of 43 SNPs in 16 candidate genes with atorvastatin response. The pharmacogenomics journal. 2005. Thompson J F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics. 2004. Foucher Christelle, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Human molecular genetics. 2004. Knoblauch Hans, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. American heart journal. 2003. Carlquist John F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes care. 2003. van Venrooij Francine V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. The New England journal of medicine. 1998. Kuivenhoven J A, et al. PubMed

LinkOuts

Entrez Gene:
1071
OMIM:
118470
143470
152430
607322
UCSC Genome Browser:
NM_000078
RefSeq RNA:
NM_000078
RefSeq Protein:
NP_000069
RefSeq DNA:
AC_000059
AC_000148
NC_000016
NG_008952
NT_010498
NW_001838290
NW_926462
UniProtKB:
CETP_HUMAN (P11597)
Ensembl:
ENSG00000087237
GenAtlas:
CETP
GeneCard:
CETP
MutDB:
CETP
ALFRED:
LO000322H
HuGE:
CETP
Comparative Toxicogenomics Database:
1071
ModBase:
P11597
HumanCyc Gene:
HS01564
HGNC:
1869

Common Searches